Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AWESOME week coming for this one... dividend, short position, low float, more news coming.... should be on the move!
I think this is gonna be a great one next week, going into the new year. I'd load up now at these levels.
HCPC updated float 3.7mil according to anotherboard.
HCPC Merger news 11,000,000 float! Moves fast.
WILMINGTON, Del.--(BUSINESS WIRE)--Heritage Capital Credit Corporation (OTC:HCPC - News) together with a related financial guaranty company First Life Financial Corporation (FLFC) announce that they have signed a non-binding Letter of Intent to merge with a London Based insurance company to form an insurance holding company based in the United States.
The new company is expected to have three divisions - a lending unit, Independent Capital Credit Corporation (ICCC); an insurance group located in the United States, FLFC; and a London based insurance unit.
FLFC will write insurance guaranty policies for transactions of the new company including the special purpose entities which will fund the proprietary BCLOC Loans originated by the lending unit. The London based insurance unit will write residual value insurance for existing financial products as well as design structured finance models for new financial products.
The new company is expected to provide a substantially larger balance sheet than existed for Heritage and with that strength the new company is expected to fund in 2007 the $740 million in ICCC's BCLOC contractual obligations.
For more information, visit our website: www.HeritageCapitalCreditCorp.com.
This press release may contain forward-looking statements within the meaning of federal securities laws that involve significant risk and uncertainties. The words "estimate," "possible," "seeking," and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risk and uncertainties, some of which cannot be predicated or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risk.
CBAY volume building gonna blow this afternoon on news.
CBAY volume picking up and gonna blow this afternoon on news.
MRKL L2's ready for breakout!
MRKL L2's ready for breakout!
MRKL L2's ready for breakout!
MRKL L2's ready for breakout!
cbay LOTS of buys
Generex Biotechnology and Fertin Pharma Announce Metformin Gum Collaboration
Wednesday May 31, 8:30 am ET
TORONTO--(MARKET WIRE)--May 31, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News), a leader in the area of buccal drug delivery, and Fertin Pharma A/S (www.fertin.com), a world leader in the development and manufacture of medicinal chewing gum, jointly announced today that they have established a collaboration for the development of a metformin medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity.
ADVERTISEMENT
Metformin is a generic drug used to regulate blood glucose (sugar) levels by reducing the amount of glucose produced by the liver, reducing the amount of glucose absorbed from food in the stomach, and by making the insulin produced by the body work more effectively to reduce the amount of glucose already in the blood. The total US market sales of all forms of metformin are approximately $1.8 Billion (IMS-MAT: December 2003).
The collaboration will seek to combine Generex's proprietary buccal drug delivery platform technologies with Fertin's know-how related to gum base formulations, solubilization systems, and taste masking/modification to create a metformin medicinal chewing gum that will deliver metformin into the body via the buccal mucosa (the inner lining of the mouth) rather than in its current tablet form. The companies expect that this new delivery method, in addition to being much more rapid and providing a much more specific and effective dosing regimen, will avoid some of the adverse side effects associated with taking metformin in tablet form such as nausea, vomiting, abdominal pain, diarrhea, abdominal bloating, and increased gas production. In addition, metformin gum will avoid the bitter taste and large doses associated with the tablet form thereby improving patient compliance, particularly amongst younger patients.
"We are pleased to have established this collaborative relationship with Fertin Pharma, the industry leader in medicinal gum," said Anna Gluskin, the Generex President & Chief Executive Officer. "Together, we will continue the Generex mission of improving diabetes care and the quality of life of people with diabetes."
Generex will conduct a pivotal clinical study to establish the non-inferiority of the product as a precursor to seeking regulatory approvals for the manufacturing, marketing, and sale of the product.
The metformin medicinal chewing gum will be a companion product to Generex Oral-lyn(TM), Generex's proprietary oral insulin spray product. Metformin is an important staple of the standard of care for patients with Type-2 diabetes mellitus. Generex believes that a combination therapy of Generex Oral-lyn, metformin gum, and other traditional oral agents can optimize the treatment of Type-2 diabetes thereby delaying the onset of complications associated with diabetes.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.
For more information, visit the Generex website at www.generex.com.
About Fertin Pharma
Fertin Pharma is a world leader in the development and manufacture of medical chewing gum and is working in partnerships with a wide range of well-respected pharmaceutical companies.
Fertin Pharma's patent protected MediChew® technology is based on unique know-how with controlled release of active substances from gum bases, fully documented release testing procedures, taste modification, and development of gum bases.
For more information, visit the Fertin Pharma website at www.fertin.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Generex Biotechnology and Fertin Pharma Announce Metformin Gum Collaboration
Wednesday May 31, 8:30 am ET
TORONTO--(MARKET WIRE)--May 31, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News), a leader in the area of buccal drug delivery, and Fertin Pharma A/S (www.fertin.com), a world leader in the development and manufacture of medicinal chewing gum, jointly announced today that they have established a collaboration for the development of a metformin medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity.
ADVERTISEMENT
Metformin is a generic drug used to regulate blood glucose (sugar) levels by reducing the amount of glucose produced by the liver, reducing the amount of glucose absorbed from food in the stomach, and by making the insulin produced by the body work more effectively to reduce the amount of glucose already in the blood. The total US market sales of all forms of metformin are approximately $1.8 Billion (IMS-MAT: December 2003).
The collaboration will seek to combine Generex's proprietary buccal drug delivery platform technologies with Fertin's know-how related to gum base formulations, solubilization systems, and taste masking/modification to create a metformin medicinal chewing gum that will deliver metformin into the body via the buccal mucosa (the inner lining of the mouth) rather than in its current tablet form. The companies expect that this new delivery method, in addition to being much more rapid and providing a much more specific and effective dosing regimen, will avoid some of the adverse side effects associated with taking metformin in tablet form such as nausea, vomiting, abdominal pain, diarrhea, abdominal bloating, and increased gas production. In addition, metformin gum will avoid the bitter taste and large doses associated with the tablet form thereby improving patient compliance, particularly amongst younger patients.
"We are pleased to have established this collaborative relationship with Fertin Pharma, the industry leader in medicinal gum," said Anna Gluskin, the Generex President & Chief Executive Officer. "Together, we will continue the Generex mission of improving diabetes care and the quality of life of people with diabetes."
Generex will conduct a pivotal clinical study to establish the non-inferiority of the product as a precursor to seeking regulatory approvals for the manufacturing, marketing, and sale of the product.
The metformin medicinal chewing gum will be a companion product to Generex Oral-lyn(TM), Generex's proprietary oral insulin spray product. Metformin is an important staple of the standard of care for patients with Type-2 diabetes mellitus. Generex believes that a combination therapy of Generex Oral-lyn, metformin gum, and other traditional oral agents can optimize the treatment of Type-2 diabetes thereby delaying the onset of complications associated with diabetes.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.
For more information, visit the Generex website at www.generex.com.
About Fertin Pharma
Fertin Pharma is a world leader in the development and manufacture of medical chewing gum and is working in partnerships with a wide range of well-respected pharmaceutical companies.
Fertin Pharma's patent protected MediChew® technology is based on unique know-how with controlled release of active substances from gum bases, fully documented release testing procedures, taste modification, and development of gum bases.
For more information, visit the Fertin Pharma website at www.fertin.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Generex Biotechnology and Fertin Pharma Announce Metformin Gum Collaboration
Wednesday May 31, 8:30 am ET
TORONTO--(MARKET WIRE)--May 31, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News), a leader in the area of buccal drug delivery, and Fertin Pharma A/S (www.fertin.com), a world leader in the development and manufacture of medicinal chewing gum, jointly announced today that they have established a collaboration for the development of a metformin medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity.
ADVERTISEMENT
Metformin is a generic drug used to regulate blood glucose (sugar) levels by reducing the amount of glucose produced by the liver, reducing the amount of glucose absorbed from food in the stomach, and by making the insulin produced by the body work more effectively to reduce the amount of glucose already in the blood. The total US market sales of all forms of metformin are approximately $1.8 Billion (IMS-MAT: December 2003).
The collaboration will seek to combine Generex's proprietary buccal drug delivery platform technologies with Fertin's know-how related to gum base formulations, solubilization systems, and taste masking/modification to create a metformin medicinal chewing gum that will deliver metformin into the body via the buccal mucosa (the inner lining of the mouth) rather than in its current tablet form. The companies expect that this new delivery method, in addition to being much more rapid and providing a much more specific and effective dosing regimen, will avoid some of the adverse side effects associated with taking metformin in tablet form such as nausea, vomiting, abdominal pain, diarrhea, abdominal bloating, and increased gas production. In addition, metformin gum will avoid the bitter taste and large doses associated with the tablet form thereby improving patient compliance, particularly amongst younger patients.
"We are pleased to have established this collaborative relationship with Fertin Pharma, the industry leader in medicinal gum," said Anna Gluskin, the Generex President & Chief Executive Officer. "Together, we will continue the Generex mission of improving diabetes care and the quality of life of people with diabetes."
Generex will conduct a pivotal clinical study to establish the non-inferiority of the product as a precursor to seeking regulatory approvals for the manufacturing, marketing, and sale of the product.
The metformin medicinal chewing gum will be a companion product to Generex Oral-lyn(TM), Generex's proprietary oral insulin spray product. Metformin is an important staple of the standard of care for patients with Type-2 diabetes mellitus. Generex believes that a combination therapy of Generex Oral-lyn, metformin gum, and other traditional oral agents can optimize the treatment of Type-2 diabetes thereby delaying the onset of complications associated with diabetes.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.
For more information, visit the Generex website at www.generex.com.
About Fertin Pharma
Fertin Pharma is a world leader in the development and manufacture of medical chewing gum and is working in partnerships with a wide range of well-respected pharmaceutical companies.
Fertin Pharma's patent protected MediChew® technology is based on unique know-how with controlled release of active substances from gum bases, fully documented release testing procedures, taste modification, and development of gum bases.
For more information, visit the Fertin Pharma website at www.fertin.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
GNBT - News gum that treats diabetes.
Generex Biotechnology and Fertin Pharma Announce Metformin Gum Collaboration
Wednesday May 31, 8:30 am ET
TORONTO--(MARKET WIRE)--May 31, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News), a leader in the area of buccal drug delivery, and Fertin Pharma A/S (www.fertin.com), a world leader in the development and manufacture of medicinal chewing gum, jointly announced today that they have established a collaboration for the development of a metformin medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity.
ADVERTISEMENT
Metformin is a generic drug used to regulate blood glucose (sugar) levels by reducing the amount of glucose produced by the liver, reducing the amount of glucose absorbed from food in the stomach, and by making the insulin produced by the body work more effectively to reduce the amount of glucose already in the blood. The total US market sales of all forms of metformin are approximately $1.8 Billion (IMS-MAT: December 2003).
The collaboration will seek to combine Generex's proprietary buccal drug delivery platform technologies with Fertin's know-how related to gum base formulations, solubilization systems, and taste masking/modification to create a metformin medicinal chewing gum that will deliver metformin into the body via the buccal mucosa (the inner lining of the mouth) rather than in its current tablet form. The companies expect that this new delivery method, in addition to being much more rapid and providing a much more specific and effective dosing regimen, will avoid some of the adverse side effects associated with taking metformin in tablet form such as nausea, vomiting, abdominal pain, diarrhea, abdominal bloating, and increased gas production. In addition, metformin gum will avoid the bitter taste and large doses associated with the tablet form thereby improving patient compliance, particularly amongst younger patients.
"We are pleased to have established this collaborative relationship with Fertin Pharma, the industry leader in medicinal gum," said Anna Gluskin, the Generex President & Chief Executive Officer. "Together, we will continue the Generex mission of improving diabetes care and the quality of life of people with diabetes."
Generex will conduct a pivotal clinical study to establish the non-inferiority of the product as a precursor to seeking regulatory approvals for the manufacturing, marketing, and sale of the product.
The metformin medicinal chewing gum will be a companion product to Generex Oral-lyn(TM), Generex's proprietary oral insulin spray product. Metformin is an important staple of the standard of care for patients with Type-2 diabetes mellitus. Generex believes that a combination therapy of Generex Oral-lyn, metformin gum, and other traditional oral agents can optimize the treatment of Type-2 diabetes thereby delaying the onset of complications associated with diabetes.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.
For more information, visit the Generex website at www.generex.com.
About Fertin Pharma
Fertin Pharma is a world leader in the development and manufacture of medical chewing gum and is working in partnerships with a wide range of well-respected pharmaceutical companies.
Fertin Pharma's patent protected MediChew® technology is based on unique know-how with controlled release of active substances from gum bases, fully documented release testing procedures, taste modification, and development of gum bases.
For more information, visit the Fertin Pharma website at www.fertin.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
STEM gapping up... it broke resistance @ 2.26 on Friday! It could be a runner!
STEM gapping up... it broke resistance @ 2.26 on Friday! It could be a runner!
STEM gapping up... it broke resistance @ 2.26 on Friday! It could be a runner!
Agree, STEM will be flying, look at the chart... big bounce coming. I loaded up today!
lol stem does look hot!
STEM BOUNCING LOOKS LIKE A GOOD PLAY
NECX BREAKS .20 TODAY WITH VOLUME!
necx breaks .20 today with decent volume
NECX RUNNING HUGE ON FINANCIALS! LOOK AT THE CHART!
NECX RUNNING HUGE ON FINANCIALS! LOOK AT THE CHART!
NECX RUNNING HUGE ON FINANCIALS! LOOK AT THE CHART!
NECX RUNNING HUGE ON FINANCIALS! LOOK AT THE CHART!
NECX RUNNING HUGE ON FINANCIALS! LOOK AT THE CHART!
GSPI gapping up, with volume it will fly! News below!
Green Star Products Unveils Advanced Biodiesel Reactor
Thursday May 25, 1:15 pm ET
SAN DIEGO, CA--(MARKET WIRE)--May 25, 2006 -- Ewire -- Green Star Products, Inc. (Other OTC:GSPI.PK - News) (GreenStarUSA.com) announced today that they have developed and successfully commercially tested their advanced biodiesel reactor.
ADVERTISEMENT
GSPI reactors require an amazing two-minutes to complete the biodiesel conversion reaction versus over one-hour for the rest of the industry. This means that GSPI's processing rate through the reactor is at least 30 times faster than the rest of the biodiesel industry.
Mr. LaStella, President of GSPI, stated, "Three different sizes of the proprietary biodiesel reactors were tested from January 2005 through February 2006 at the Bakersfield Biodiesel Plant Facility. The largest reactor was rated at 10-million GPYC (gallons per year capacity) and was operated from August 2005 through February 2006."
Mr. LaStella further stated, "The reactor's capability is revolutionary. Most biodiesel plants processes require from one to one-and-a-half hours for complete chemical reactions to take place between vegetable oil, alcohol (methanol) and the catalyst. The GSPI reactors take less than two-minutes to complete the reactions. Furthermore, the advanced engineering design incorporates an inexpensive construction method to produce these reactors. The basic production cost to build them has been reduced to only $30,000 per reactor for a 10-million GPYC module. Smaller units will cost even less. This major engineering breakthrough will significantly reduce the costs and time to build biodiesel plants. The balance of the infrastructure -- which includes land, building, electrical, storage facilities, railroad access and final cleanup of biodiesel, will still be required."
Mr. LaStella further noted, "Most biodiesel plants also need large amounts of water to clean the biodiesel after completion of initial reaction conversion to attain quality ASTM grade biodiesel. GSPI also has been using a proprietary Waterless Biodiesel Cleanup System since December 2003 at the Bakersfield facility. GSPI's cleanup system negates the need for complex permits and significantly reduces construction expenditures associated with washing systems normally used in the industry."
For the full release please click on the following link: http://www.ewire.com/display.cfm/Wire_ID/3100
Contact:
CONTACT:
Joseph LaStella
President
Green Star Products, Inc.
Chula Vista, Calif.
619-864-4010
619-789-4743 (fax)
Email Contact
GSPI gapping up, with volume it will fly! News below!
Green Star Products Unveils Advanced Biodiesel Reactor
Thursday May 25, 1:15 pm ET
SAN DIEGO, CA--(MARKET WIRE)--May 25, 2006 -- Ewire -- Green Star Products, Inc. (Other OTC:GSPI.PK - News) (GreenStarUSA.com) announced today that they have developed and successfully commercially tested their advanced biodiesel reactor.
ADVERTISEMENT
GSPI reactors require an amazing two-minutes to complete the biodiesel conversion reaction versus over one-hour for the rest of the industry. This means that GSPI's processing rate through the reactor is at least 30 times faster than the rest of the biodiesel industry.
Mr. LaStella, President of GSPI, stated, "Three different sizes of the proprietary biodiesel reactors were tested from January 2005 through February 2006 at the Bakersfield Biodiesel Plant Facility. The largest reactor was rated at 10-million GPYC (gallons per year capacity) and was operated from August 2005 through February 2006."
Mr. LaStella further stated, "The reactor's capability is revolutionary. Most biodiesel plants processes require from one to one-and-a-half hours for complete chemical reactions to take place between vegetable oil, alcohol (methanol) and the catalyst. The GSPI reactors take less than two-minutes to complete the reactions. Furthermore, the advanced engineering design incorporates an inexpensive construction method to produce these reactors. The basic production cost to build them has been reduced to only $30,000 per reactor for a 10-million GPYC module. Smaller units will cost even less. This major engineering breakthrough will significantly reduce the costs and time to build biodiesel plants. The balance of the infrastructure -- which includes land, building, electrical, storage facilities, railroad access and final cleanup of biodiesel, will still be required."
Mr. LaStella further noted, "Most biodiesel plants also need large amounts of water to clean the biodiesel after completion of initial reaction conversion to attain quality ASTM grade biodiesel. GSPI also has been using a proprietary Waterless Biodiesel Cleanup System since December 2003 at the Bakersfield facility. GSPI's cleanup system negates the need for complex permits and significantly reduces construction expenditures associated with washing systems normally used in the industry."
For the full release please click on the following link: http://www.ewire.com/display.cfm/Wire_ID/3100
Contact:
CONTACT:
Joseph LaStella
President
Green Star Products, Inc.
Chula Vista, Calif.
619-864-4010
619-789-4743 (fax)
Email Contact
GSPI gapping up, with volume it will fly! News below!
Green Star Products Unveils Advanced Biodiesel Reactor
Thursday May 25, 1:15 pm ET
SAN DIEGO, CA--(MARKET WIRE)--May 25, 2006 -- Ewire -- Green Star Products, Inc. (Other OTC:GSPI.PK - News) (GreenStarUSA.com) announced today that they have developed and successfully commercially tested their advanced biodiesel reactor.
ADVERTISEMENT
GSPI reactors require an amazing two-minutes to complete the biodiesel conversion reaction versus over one-hour for the rest of the industry. This means that GSPI's processing rate through the reactor is at least 30 times faster than the rest of the biodiesel industry.
Mr. LaStella, President of GSPI, stated, "Three different sizes of the proprietary biodiesel reactors were tested from January 2005 through February 2006 at the Bakersfield Biodiesel Plant Facility. The largest reactor was rated at 10-million GPYC (gallons per year capacity) and was operated from August 2005 through February 2006."
Mr. LaStella further stated, "The reactor's capability is revolutionary. Most biodiesel plants processes require from one to one-and-a-half hours for complete chemical reactions to take place between vegetable oil, alcohol (methanol) and the catalyst. The GSPI reactors take less than two-minutes to complete the reactions. Furthermore, the advanced engineering design incorporates an inexpensive construction method to produce these reactors. The basic production cost to build them has been reduced to only $30,000 per reactor for a 10-million GPYC module. Smaller units will cost even less. This major engineering breakthrough will significantly reduce the costs and time to build biodiesel plants. The balance of the infrastructure -- which includes land, building, electrical, storage facilities, railroad access and final cleanup of biodiesel, will still be required."
Mr. LaStella further noted, "Most biodiesel plants also need large amounts of water to clean the biodiesel after completion of initial reaction conversion to attain quality ASTM grade biodiesel. GSPI also has been using a proprietary Waterless Biodiesel Cleanup System since December 2003 at the Bakersfield facility. GSPI's cleanup system negates the need for complex permits and significantly reduces construction expenditures associated with washing systems normally used in the industry."
For the full release please click on the following link: http://www.ewire.com/display.cfm/Wire_ID/3100
Contact:
CONTACT:
Joseph LaStella
President
Green Star Products, Inc.
Chula Vista, Calif.
619-864-4010
619-789-4743 (fax)
Email Contact
If you want to leave ameritrade you might try Etrade or Choicetrade.
I looked at tradeking they are not good for pennies they charge you per share after a certain amount.
Does anyone know if Ameritrade's L2 covers OTC and Pinks? I just got upgraded to Apex, so I can get it for free now and just curious. If so I can drop Alphatrade.
Great day I think... very good IPO and should continue to climb. What are peoples opinions?
GSPI gonna be big, news below. Look at the chart, runs always start with a small candlestick then a big one the next couple days! Get in early!
Green Star Products Unveils Advanced Biodiesel Reactor
Thursday May 25, 1:15 pm ET
SAN DIEGO, CA--(MARKET WIRE)--May 25, 2006 -- Ewire -- Green Star Products, Inc. (Other OTC:GSPI.PK - News) (GreenStarUSA.com) announced today that they have developed and successfully commercially tested their advanced biodiesel reactor.
GSPI reactors require an amazing two-minutes to complete the biodiesel conversion reaction versus over one-hour for the rest of the industry. This means that GSPI's processing rate through the reactor is at least 30 times faster than the rest of the biodiesel industry.
Mr. LaStella, President of GSPI, stated, "Three different sizes of the proprietary biodiesel reactors were tested from January 2005 through February 2006 at the Bakersfield Biodiesel Plant Facility. The largest reactor was rated at 10-million GPYC (gallons per year capacity) and was operated from August 2005 through February 2006."
Mr. LaStella further stated, "The reactor's capability is revolutionary. Most biodiesel plants processes require from one to one-and-a-half hours for complete chemical reactions to take place between vegetable oil, alcohol (methanol) and the catalyst. The GSPI reactors take less than two-minutes to complete the reactions. Furthermore, the advanced engineering design incorporates an inexpensive construction method to produce these reactors. The basic production cost to build them has been reduced to only $30,000 per reactor for a 10-million GPYC module. Smaller units will cost even less. This major engineering breakthrough will significantly reduce the costs and time to build biodiesel plants. The balance of the infrastructure -- which includes land, building, electrical, storage facilities, railroad access and final cleanup of biodiesel, will still be required."
Mr. LaStella further noted, "Most biodiesel plants also need large amounts of water to clean the biodiesel after completion of initial reaction conversion to attain quality ASTM grade biodiesel. GSPI also has been using a proprietary Waterless Biodiesel Cleanup System since December 2003 at the Bakersfield facility. GSPI's cleanup system negates the need for complex permits and significantly reduces construction expenditures associated with washing systems normally used in the industry."
For the full release please click on the following link: http://www.ewire.com/display.cfm/Wire_ID/3100
Contact:
CONTACT:
Joseph LaStella
President
Green Star Products, Inc.
Chula Vista, Calif.
619-864-4010
619-789-4743 (fax)
Email Contact
GSPI gonna be big, news below. Look at the chart, runs always start with a small candlestick then a big one the next couple days! Get in early!
Green Star Products Unveils Advanced Biodiesel Reactor
Thursday May 25, 1:15 pm ET
SAN DIEGO, CA--(MARKET WIRE)--May 25, 2006 -- Ewire -- Green Star Products, Inc. (Other OTC:GSPI.PK - News) (GreenStarUSA.com) announced today that they have developed and successfully commercially tested their advanced biodiesel reactor.
GSPI reactors require an amazing two-minutes to complete the biodiesel conversion reaction versus over one-hour for the rest of the industry. This means that GSPI's processing rate through the reactor is at least 30 times faster than the rest of the biodiesel industry.
Mr. LaStella, President of GSPI, stated, "Three different sizes of the proprietary biodiesel reactors were tested from January 2005 through February 2006 at the Bakersfield Biodiesel Plant Facility. The largest reactor was rated at 10-million GPYC (gallons per year capacity) and was operated from August 2005 through February 2006."
Mr. LaStella further stated, "The reactor's capability is revolutionary. Most biodiesel plants processes require from one to one-and-a-half hours for complete chemical reactions to take place between vegetable oil, alcohol (methanol) and the catalyst. The GSPI reactors take less than two-minutes to complete the reactions. Furthermore, the advanced engineering design incorporates an inexpensive construction method to produce these reactors. The basic production cost to build them has been reduced to only $30,000 per reactor for a 10-million GPYC module. Smaller units will cost even less. This major engineering breakthrough will significantly reduce the costs and time to build biodiesel plants. The balance of the infrastructure -- which includes land, building, electrical, storage facilities, railroad access and final cleanup of biodiesel, will still be required."
Mr. LaStella further noted, "Most biodiesel plants also need large amounts of water to clean the biodiesel after completion of initial reaction conversion to attain quality ASTM grade biodiesel. GSPI also has been using a proprietary Waterless Biodiesel Cleanup System since December 2003 at the Bakersfield facility. GSPI's cleanup system negates the need for complex permits and significantly reduces construction expenditures associated with washing systems normally used in the industry."
For the full release please click on the following link: http://www.ewire.com/display.cfm/Wire_ID/3100
Contact:
CONTACT:
Joseph LaStella
President
Green Star Products, Inc.
Chula Vista, Calif.
619-864-4010
619-789-4743 (fax)
Email Contact
GSPI gonna be big, news below. Look at the chart, runs always start with a small candlestick then a big one the next couple days! Get in early!
Green Star Products Unveils Advanced Biodiesel Reactor
Thursday May 25, 1:15 pm ET
SAN DIEGO, CA--(MARKET WIRE)--May 25, 2006 -- Ewire -- Green Star Products, Inc. (Other OTC:GSPI.PK - News) (GreenStarUSA.com) announced today that they have developed and successfully commercially tested their advanced biodiesel reactor.
GSPI reactors require an amazing two-minutes to complete the biodiesel conversion reaction versus over one-hour for the rest of the industry. This means that GSPI's processing rate through the reactor is at least 30 times faster than the rest of the biodiesel industry.
Mr. LaStella, President of GSPI, stated, "Three different sizes of the proprietary biodiesel reactors were tested from January 2005 through February 2006 at the Bakersfield Biodiesel Plant Facility. The largest reactor was rated at 10-million GPYC (gallons per year capacity) and was operated from August 2005 through February 2006."
Mr. LaStella further stated, "The reactor's capability is revolutionary. Most biodiesel plants processes require from one to one-and-a-half hours for complete chemical reactions to take place between vegetable oil, alcohol (methanol) and the catalyst. The GSPI reactors take less than two-minutes to complete the reactions. Furthermore, the advanced engineering design incorporates an inexpensive construction method to produce these reactors. The basic production cost to build them has been reduced to only $30,000 per reactor for a 10-million GPYC module. Smaller units will cost even less. This major engineering breakthrough will significantly reduce the costs and time to build biodiesel plants. The balance of the infrastructure -- which includes land, building, electrical, storage facilities, railroad access and final cleanup of biodiesel, will still be required."
Mr. LaStella further noted, "Most biodiesel plants also need large amounts of water to clean the biodiesel after completion of initial reaction conversion to attain quality ASTM grade biodiesel. GSPI also has been using a proprietary Waterless Biodiesel Cleanup System since December 2003 at the Bakersfield facility. GSPI's cleanup system negates the need for complex permits and significantly reduces construction expenditures associated with washing systems normally used in the industry."
For the full release please click on the following link: http://www.ewire.com/display.cfm/Wire_ID/3100
Contact:
CONTACT:
Joseph LaStella
President
Green Star Products, Inc.
Chula Vista, Calif.
619-864-4010
619-789-4743 (fax)
Email Contact
GSPI gonna be big, news below. Look at the chart, runs always start with a small candlestick then a big one the next couple days! Get in early!
Green Star Products Unveils Advanced Biodiesel Reactor
Thursday May 25, 1:15 pm ET
SAN DIEGO, CA--(MARKET WIRE)--May 25, 2006 -- Ewire -- Green Star Products, Inc. (Other OTC:GSPI.PK - News) (GreenStarUSA.com) announced today that they have developed and successfully commercially tested their advanced biodiesel reactor.
GSPI reactors require an amazing two-minutes to complete the biodiesel conversion reaction versus over one-hour for the rest of the industry. This means that GSPI's processing rate through the reactor is at least 30 times faster than the rest of the biodiesel industry.
Mr. LaStella, President of GSPI, stated, "Three different sizes of the proprietary biodiesel reactors were tested from January 2005 through February 2006 at the Bakersfield Biodiesel Plant Facility. The largest reactor was rated at 10-million GPYC (gallons per year capacity) and was operated from August 2005 through February 2006."
Mr. LaStella further stated, "The reactor's capability is revolutionary. Most biodiesel plants processes require from one to one-and-a-half hours for complete chemical reactions to take place between vegetable oil, alcohol (methanol) and the catalyst. The GSPI reactors take less than two-minutes to complete the reactions. Furthermore, the advanced engineering design incorporates an inexpensive construction method to produce these reactors. The basic production cost to build them has been reduced to only $30,000 per reactor for a 10-million GPYC module. Smaller units will cost even less. This major engineering breakthrough will significantly reduce the costs and time to build biodiesel plants. The balance of the infrastructure -- which includes land, building, electrical, storage facilities, railroad access and final cleanup of biodiesel, will still be required."
Mr. LaStella further noted, "Most biodiesel plants also need large amounts of water to clean the biodiesel after completion of initial reaction conversion to attain quality ASTM grade biodiesel. GSPI also has been using a proprietary Waterless Biodiesel Cleanup System since December 2003 at the Bakersfield facility. GSPI's cleanup system negates the need for complex permits and significantly reduces construction expenditures associated with washing systems normally used in the industry."
For the full release please click on the following link: http://www.ewire.com/display.cfm/Wire_ID/3100
Contact:
CONTACT:
Joseph LaStella
President
Green Star Products, Inc.
Chula Vista, Calif.
619-864-4010
619-789-4743 (fax)
Email Contact
GSPI gonna be big, news below. Look at the chart, runs always start with a small candlestick then a big one the next couple days! Get in early!
Green Star Products Unveils Advanced Biodiesel Reactor
Thursday May 25, 1:15 pm ET
SAN DIEGO, CA--(MARKET WIRE)--May 25, 2006 -- Ewire -- Green Star Products, Inc. (Other OTC:GSPI.PK - News) (GreenStarUSA.com) announced today that they have developed and successfully commercially tested their advanced biodiesel reactor.
GSPI reactors require an amazing two-minutes to complete the biodiesel conversion reaction versus over one-hour for the rest of the industry. This means that GSPI's processing rate through the reactor is at least 30 times faster than the rest of the biodiesel industry.
Mr. LaStella, President of GSPI, stated, "Three different sizes of the proprietary biodiesel reactors were tested from January 2005 through February 2006 at the Bakersfield Biodiesel Plant Facility. The largest reactor was rated at 10-million GPYC (gallons per year capacity) and was operated from August 2005 through February 2006."
Mr. LaStella further stated, "The reactor's capability is revolutionary. Most biodiesel plants processes require from one to one-and-a-half hours for complete chemical reactions to take place between vegetable oil, alcohol (methanol) and the catalyst. The GSPI reactors take less than two-minutes to complete the reactions. Furthermore, the advanced engineering design incorporates an inexpensive construction method to produce these reactors. The basic production cost to build them has been reduced to only $30,000 per reactor for a 10-million GPYC module. Smaller units will cost even less. This major engineering breakthrough will significantly reduce the costs and time to build biodiesel plants. The balance of the infrastructure -- which includes land, building, electrical, storage facilities, railroad access and final cleanup of biodiesel, will still be required."
Mr. LaStella further noted, "Most biodiesel plants also need large amounts of water to clean the biodiesel after completion of initial reaction conversion to attain quality ASTM grade biodiesel. GSPI also has been using a proprietary Waterless Biodiesel Cleanup System since December 2003 at the Bakersfield facility. GSPI's cleanup system negates the need for complex permits and significantly reduces construction expenditures associated with washing systems normally used in the industry."
For the full release please click on the following link: http://www.ewire.com/display.cfm/Wire_ID/3100
Contact:
CONTACT:
Joseph LaStella
President
Green Star Products, Inc.
Chula Vista, Calif.
619-864-4010
619-789-4743 (fax)
Email Contact